Confident prediction of who will or will not experience side effects from a cornerstone heart failure therapy continues to elude researchers, even as they showed that some real-world patients were ...

Two weeks ago, Novartis CEO Vas Narasimhan referred to the initial wave of drug pricing effects tied to the Inflation Reduction Act (IRA) as “manageable.” What the company appears to be finding ...

Novartis has started to feel the squeeze from generics to its top-selling drug, heart therapy Entresto. The erosion was obvious. After MSN Pharmaceuticals opened the floodgates to Entresto generics in ...